61364-20-3

Basic information

• Product Name: 3,4-dihydro-Cyclopent[b]indol-1(2H)-one
• Synonyms: 3,4-dihydro-Cyclopent[b]indol-1(2H)-one;2,3-dihydrocyclopenta[b]indol-1(4H)-one;OC1171, 2,3-Dihydrocyclopenta[b]indol-1(4H)-one
• CAS NO: 61364-20-3
• Molecular Formula: C₁₁H₉NO
• Molecular Weight: 171.19526
• Mol File: 61364-20-3.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,4-dihydro-Cyclopent[b]indol-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dihydro-Cyclopent[b]indol-1(2H)-one(61364-20-3)
• EPA Substance Registry System: 3,4-dihydro-Cyclopent[b]indol-1(2H)-one(61364-20-3)

Safety Data

• Hazardous Substances Data: 61364-20-3(Hazardous Substances Data)

Usage

Description

3,4-dihydro-Cyclopent[b]indol-1(2H)-one, also known as tetrahydrocarboline, is a bicyclic chemical compound featuring a lactam functional group. It is commonly found in various natural products and pharmaceuticals and has been studied for its potential pharmacological activities, including neuroprotective, anti-inflammatory, and anticancer properties. Its structural diversity and biological activities make it a promising candidate for drug discovery and development. Furthermore, 3,4-dihydro-Cyclopent[b]indol-1(2H)-one has been investigated for its role in the central nervous system and its potential as a therapeutic agent for various medical conditions.

Uses

Used in Pharmaceutical Industry:
3,4-dihydro-Cyclopent[b]indol-1(2H)-one is used as a pharmaceutical compound for its neuroprotective, anti-inflammatory, and anticancer properties. Its potential pharmacological activities make it a promising candidate for the development of new drugs to treat various medical conditions.
Used in Drug Discovery and Development:
3,4-dihydro-Cyclopent[b]indol-1(2H)-one is used as a structural template in drug discovery and development due to its diverse biological activities and potential for further modification to enhance its therapeutic effects.
Used in Central Nervous System Research:
3,4-dihydro-Cyclopent[b]indol-1(2H)-one is used as a research compound in the study of the central nervous system, with potential applications as a therapeutic agent for various neurological and psychiatric conditions.

Upstream product

• 2047-91-8 2,3-dihydro-1H-cyclopentindole 
• 73825-35-1 3-(N-phenylamino)-2-cyclopentene-1-one 
• 443303-78-4 2-(2-nitrophenyl)-2-cyclopenten-1-one 
• 615-36-1 2-bromoaniline 
• 33948-35-5 2-iodo-cyclopent-2-enone 
• 79062-30-9 2-(tri-n-butylstannyl)-1-nitrobenzene 
• 62-53-3 aniline 
• 29873-09-4 4-(1H-indol-2-yl)butanoic acid 
• 364328-33-6 3-hydroxy-2-(2-nitrophenyl)-1H-inden-1-one 
• 615-43-0 2-iodophenylamine 
• 61765-46-6 3-iodo-cyclopentenone 

Relevant articles and documents

Tandem Ullmann-Goldberg Cross-Coupling/Cyclopalladation-Reductive Elimination Reactions and Related Sequences Leading to Polyfunctionalized Benzofurans, Indoles, and Phthalanes

On exposure to a combination of Cu[I]- and Pd[0]-based catalysts, compounds such as 1 and 7 engage in tandem Ullmann-Goldberg cross-coupling and cyclopalladation-reductive elimination reactions to give benzofurans such as 8. Related reactions involving hetero-Michael additions of o-halogenated phenols or anilines to propiolates and the Pd[0]-catalyzed cyclization of the resulting conjugates provide, in a one-pot process, alternately functionalized benzofurans, indoles, or phthalanes.

An easy access to carbazolones and 2,3-disubstituted indoles

Synthesis of carbazol-4-ones, 3,4-dihydrocyclopental-indol-1-one, and indole derivatives by a Fe/AcOH-mediated intramolecular reductive N-heteroannulation of 3-hydroxy-2-(2-nitrophenyl)enones is demonstrated. The same protocol has been extended to access indolocarbazolone and indoloquinolone derivatives. Synthesis ofderivatives by a Fe/AcOH-mediated intramolecular reductive N-heteroannulation strategy is demonstrated. The starting materials were easily accessed from C-arylation of 1,3-diketones by o-nitroiodobenzenes. Copyright

TRICYCLIC CYTOPROTECTIVE COMPOUNDS

Compounds of formula (I): in which: X is a group of formula >CR1R2 or >SO2; Y is a group of formula >NH or >CR1R2; Z is a group of formula >C=O or >CH2 or a direct bond; R1 hydrogen and R2 is hydrogen, carboxy or hydroxy; or R1 and R2 together represent an oxo group, a methylenedioxy group or a hydroxyimino group; R3 is hydrogen or lower alkyl; R4 represents two hydrogen atoms, or an oxo or hydroxyimino group; R5 is hydrogen, lower alkyl or halogen; R6 is hydrogen, lower alkoxy or carboxy; R7 and R8 are each hydrogen, lower alkyl or halogen; and pharmaceutically acceptable salts and esters thereof can be used for the treatment or prophylaxis of acute or chronic neurodegenerative diseases or conditions such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Chorea, Multiple Sclerosis or the sequelae to acute ischaemic events such as heart attack, stroke or head injury and for protection against ischaemic damage to tissues of peripheral organs.